

## **Biostatistics Certificate**

December 12, 2023

To whom it concerns.

**RE: Combined prognostic value of serum CA 19-9 and tumor size reduction ratio in patients with pancreatic ductal adenocarcinoma undergoing neoadjuvant therapy**

This letter is to confirm that I have read the ethics application prepared for this study, and that in my opinion the statistical methods and techniques mentioned in this study are appropriate for the research.

Please do not hesitate to communicate with my office should you have any questions or require any additional information.

Sincerely,  
Yongtao Wang

Massachusetts  
General Hospital and Harvard Medical School, Division of  
Gastrointestinal and Oncologic Surgery, Boston, United States